R
RenovoRx, Inc. (RNXT)
1.13
0.00 (0.00%)
Get all premium features to the best stock analysis tool
1.13
0.00 (0.00%)
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
| Name | Position |
|---|---|
| Dr. Ramtin Agah M.D. | Founder, Chairman of Board & Chief Medical Officer |
| Mr. Mark Voll | CFO & Principal Accounting Officer |
| Mr. Robert Strasser | Vice President of Operations and R&D |
| Mr. Ronald B. Kocak CPA, CGMA | VP of Finance & Controller |
| Mr. Ryan Witt | Senior VP and Head of Corporate Strategy & Partnerships |
| Mr. Shaun R. Bagai | CEO, Secretary & Director |
| Ms. Leesa Gentry | Chief Clinical Officer |
| Date | Type | Document |
|---|---|---|
| 2026-01-02 | 8-K | form8-k.htm |
| 2025-11-14 | 8-K | form8-k.htm |
| 2025-11-13 | 10-Q | form10-q.htm |
| 2025-08-14 | 10-Q | form10-q.htm |
| 2025-08-13 | CORRESP | filename1.htm |
| 2025-07-18 | CORRESP | filename1.htm |
| 2025-06-27 | S-8 | forms-8.htm |
| 2025-06-25 | 8-K | form8-k.htm |
| 2025-05-15 | 8-K | form8-k.htm |
| 2025-04-30 | DEF 14A | formdef14a.htm |